10-Year Observational Survival Study at IHC

10-Year Observational Survival Study on an Integrative Naturopathic Treatment Model Including Modulated Electrohyperthermia (mEHT): A Single-Centre Experience.

Gurdev Parmar¹, Leanna Standish², Sarah Denotter¹

¹Integrated Health Clinic, White Rock & Fort Langley, B.C., Canada. ²AIMS Institute, Seattle, WA, USA

Abstract

There is a considerable amount of research supporting the use of integrative naturopathic methods, including modulated electrohyperthermia (mEHT), in an oncology setting. This investigation examines survival outcomes in consecutive cases of the ten most commonly treated stage IV cancers in our clinics between 2010 and 2020.

Data was collected by reviewing historical IHC patient charts, extracting the necessary data, and including only those patients who fit the study inclusion criteria into a protected data base. The main analysis was to determine overall survival rates in those patients with metastatic stage IV solid tumours. Patients were followed until death, censoring, or the end of study. Kaplan-Meier non-parametric survival estimates were calculated and plotted for all patients in the qualified cohort. The analysis was conducted using SAS software version 9.3 (SAS Institute Inc, Cary, NC). Using the SEER database to match IHC patients with SEER patients based on age of diagnosis and sex, we provide 5- and 10-year survival comparisons to the SEER database.

mEHT was applied using the Oncotherm EHY-2000+ device, and was integrated with conventional and naturopathic treatments. An examination of the data from all consecutively treated patients over the 10-years is provided.  mEHT has now been safely administered to thousands of patients, completing over 30,000 treatments in over 35 cancer types in our centre.  For this particular study, data elements include patient demographics, statistics, treatment(s) used, adverse events, overall survival (OS), diagnostic imaging & blood test results.

mEHT is a safe treatment used alongside radiotherapy, chemotherapy, immunotherapy, targeted therapies, and various adjunctive naturopathic treatments. We also present very few adverse events, allowing patients to maintain a high quality of life.  Our encouraging data supports the addition of mEHT into an integrative oncology setting, providing patients with clinically significant benefits to PFS and OS, as well as to QoL.

If you have questions contact the clinic via our website at www.integratedhealthclinic.com or 604-888-8325

Dr. Gurdev Parmar, ND